Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 29 Apr 2017

These Bioartists Turn Cell-to-Cell Communication in your Body into Sound

Thought Collider and David Young have developed an installation that transforms the faint communication signals between your skin cells into sounds. Artist duo Thought Collider is comprised of Mike Thompson, from the UK, and Susana Cámara Leret, from Spain. Based in Amsterdam and London, they experiment with the living nature of our bodies and microorganisms. Their […]

April 29, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Apr 2017

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […]

April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 26 Apr 2017

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

The young field of mRNA therapeutics is booming and generating huge expectations. Which are the main players in Europe turning them into a reality? Therapies based on mRNA promise better vaccines and therapeutics by instructing the body to produce its own just by reading the instructions written in the RNA sequence. Thought for a long time to […]

April 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 24 Apr 2017

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […]

April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview Mark Post cultured meat Mosa Meat

Interview 24 Apr 2017

‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for

Mark Post is a researcher at the University of Maastricht and co-founder and CSO of Mosa Meat, the Dutch company that will bring the first lab-grown beef burger to the market. I asked him about his motivations and plans to make cultured meat a reality in the coming decade. Cultured meat is an animal-free, lab-grown […]

April 24, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Apr 2017

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […]

April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Stefan Weber CEO Newron Pharmaceuticals Labiotech Meetup Munich

Interview 20 Apr 2017

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Philip talked to Stefan Weber, CEO of Newron Pharmaceuticals, in our first meetup in Munich last week. His company has launched a new drug that could offer many more benefits than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Apr 2017

New French Biotech Seed Fund Raises €65M in its First Closing

Advent France Biotechnology has launched its first seed fund for Life Sciences with the support of Bpifrance and Advent Life Sciences. Advent France Biotechnology, founded in 2015, has exceeded its initial fundraising target at the first closing. Its Seed-Fund I now counts with €64.75M that will be invested predominantly in France. The funds will back entrepreneurs […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 18 Apr 2017

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […]

April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Apr 2017

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Transgene Pexa Vec Oncolytic Virus Vaccine

News and Trends 13 Apr 2017

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

These Bioartists Turn Cell-to-Cell Communication in your Body into Sound

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Infographic: Who’s who in the mRNA Therapeutics Field in Europe?

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

New French Biotech Seed Fund Raises €65M in its First Closing

Which EU Immuno-Oncology Company are you Cheering for?

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!